Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mahonia aquifolium is a flowering evergreen shrub native to the Pacific Northwest of North America and commonly known as Oregon grape. Its root and wood contain isoquinoline alkaloids such as berberine, jatrorrhizine, palmatine, and magnoflorine. These compounds are believed to provide antimicrobial (antibacterial and antifungal) and anti-inflammatory effects. Mahonia aquifolium has been used in traditional medicine for skin conditions like psoriasis and atopic dermatitis; clinical studies have shown topical preparations can reduce symptoms in mild to moderate cases. The primary mechanism of action is thought to be inhibition of keratinocyte growth (relevant for psoriasis) along with antimicrobial activity due to berberine content[1][2][3][5]. It is available in various forms including creams (such as Reliéva), extracts, supplements, oils, and tinctures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mahonia aquifolium.